Status: Recruiting
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.
Participants needed: 15
Trial details
Phase: Phase 1, Phase 2Age: 1-21Biological sex: AllType: InterventionalSponsor: Eureka Therapeutics Inc.Updated: Apr 9, 2025Locations: 2
Eligibility criteria
Histologically confirmed HB, HCN-NOS, or HCC with serum AFP >100ng/mL at the tim... [+8]
Recurrent HB who are candidates for complete surgical resection (e.g., isolated... [+11]